Medtronic plc (MDT)
Medtronic: A Dividend Aristocrat At A Steal Now
Medtronic plc is a sleepy Dividend Aristocrat with the potential for dividend growth to reaccelerate in the next 12 to 24 months. MDT beat the analyst consensus for revenue and non-GAAP EPS in Q4 2026, with the highest annual revenue growth in 10 years. Medtronic sports an A S&P credit rating with a stable outlook.
Is Medtronic (MDT) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Medtronic Bottoms, Healthy Rebound Ahead
Medtronic's NYSE: MDT primary catalyst as mid-year approaches is that headwinds are not impairing results as much as feared. Rising costs, margin compression, and general uncertainty linked to macroeconomic headwinds were reflected in the company's June 3 earnings results, but the results were inherently strong and expected to remain so.
MDT Q4 Earnings Call Points to Another Year of Growth
MDT touts FY26 as a turning point, keeps FY27 growth targets high, and spotlights CAS and new platforms as investors press on tariffs and TAVR.
Medtronic Q4 Earnings and Revenues Beat, Stock Rises in Pre-Market
MDT tops Q4 revenue and earnings estimates as Cardiovascular strength and Cardiac Ablation growth fuel results, while FY27 guidance points higher.
Medtronic (MDT) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Medtronic (MDT) give a sense of how the business performed in the quarter ended April 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Medtronic Q4 Earnings Call Highlights
Medtronic NYSE: MDT reported what executives described as its strongest top-line performance in a decade, as growth in cardiac ablation, diabetes, medical-surgical products and select neuroscience platforms helped drive fiscal fourth-quarter and full-year results above expectations.
Medtronic (MDT) Q4 Earnings and Revenues Surpass Estimates
Medtronic (MDT) came out with quarterly earnings of $1.55 per share, beating the Zacks Consensus Estimate of $1.54 per share. This compares to earnings of $1.62 per share a year ago.
Medtronic Posts Higher Profit, Sales
Medtronic said its profit and sales rose during its fiscal fourth quarter, reflecting steps the company has taken to improve business performance and drive growth.
Seeking Clues to Medtronic (MDT) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of Medtronic (MDT) for the quarter ended April 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Analysts Estimate Medtronic (MDT) to Report a Decline in Earnings: What to Look Out for
Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medtronic (MDT) Stock Drops Despite Market Gains: Important Facts to Note
In the closing of the recent trading day, Medtronic (MDT) stood at $77.6, denoting a -1.27% move from the preceding trading day.
